Published in J Biol Chem on January 30, 2003
Arrangement of L2 within the papillomavirus capsid. J Virol (2008) 2.37
A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36
Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog (2012) 1.76
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol (2007) 1.70
Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J Virol (2005) 1.61
The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. J Virol (2005) 1.53
Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol (2004) 1.27
Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes. PLoS One (2009) 1.25
The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol (2013) 1.20
Virus activated filopodia promote human papillomavirus type 31 uptake from the extracellular matrix. Virology (2008) 1.10
L2, the minor capsid protein of papillomavirus. Virology (2013) 1.07
The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA binding. J Virol (2004) 1.06
The l2 minor capsid protein of low-risk human papillomavirus type 11 interacts with host nuclear import receptors and viral DNA. J Virol (2006) 1.03
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Vesicular trafficking of incoming human papillomavirus 16 to the Golgi apparatus and endoplasmic reticulum requires γ-secretase activity. MBio (2014) 1.00
Host-cell factors involved in papillomavirus entry. Med Microbiol Immunol (2012) 0.92
Differential dependence on host cell glycosaminoglycans for infection of epithelial cells by high-risk HPV types. PLoS One (2013) 0.91
Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol (2014) 0.87
The high risk HPV16 L2 minor capsid protein has multiple transport signals that mediate its nucleocytoplasmic traffic. Virology (2011) 0.85
Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody. PLoS One (2015) 0.81
Cleavage of the HPV16 Minor Capsid Protein L2 during Virion Morphogenesis Ablates the Requirement for Cellular Furin during De Novo Infection. Viruses (2015) 0.78
Study of infectious virus production from HPV18/16 capsid chimeras. Virology (2010) 0.78
A central region in the minor capsid protein of papillomaviruses facilitates viral genome tethering and membrane penetration for mitotic nuclear entry. PLoS Pathog (2017) 0.76
Developments in L2-based human papillomavirus (HPV) vaccines. Virus Res (2016) 0.76
The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis. J Virol (2016) 0.75
Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med (2009) 5.25
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res (2006) 2.92
A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol (2008) 2.22
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A (2008) 2.00
Serologic evidence for exposure to simian virus 40 in North American zoo workers. J Infect Dis (2004) 1.98
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
Population genetics of microbial pathogens estimated from multilocus sequence typing (MLST) data. Infect Genet Evol (2005) 1.72
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol (2007) 1.70
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68
Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J Virol (2005) 1.61
Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol (2009) 1.55
Phylogenomics and molecular evolution of polyomaviruses. Adv Exp Med Biol (2006) 1.54
Lack of serological evidence for an association between simian virus 40 and lymphoma. Int J Cancer (2003) 1.51
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol (2014) 1.46
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res (2006) 1.41
Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study). Cancer Epidemiol Biomarkers Prev (2011) 1.37
A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis (2004) 1.36
Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral Oncol (2007) 1.34
Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res (2008) 1.33
Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res (2012) 1.31
A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis (2012) 1.30
Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis (2009) 1.29
Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res (2006) 1.28
Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev (2007) 1.28
Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol (2004) 1.27
Population genetic estimation of the loss of genetic diversity during horizontal transmission of HIV-1. BMC Evol Biol (2006) 1.27
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res (2006) 1.26
Comparing phylogenetic codivergence between polyomaviruses and their hosts. J Virol (2006) 1.25
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25
Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause (2014) 1.21
Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 1.21
Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol (2009) 1.18
B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol (2005) 1.16
Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res (2009) 1.14
Papillomavirus infection requires gamma secretase. J Virol (2010) 1.12
Temporal trends in gonococcal population genetics in a high prevalence urban community. Infect Genet Evol (2006) 1.12
Immunoglobulin G, A, and M responses to BK virus in renal transplantation. Clin Vaccine Immunol (2006) 1.12
Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther (2005) 1.10
Serological pattern consistent with infection with type I Toxoplasma gondii in mothers and risk of psychosis among adult offspring. Microbes Infect (2009) 1.09
Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort. J Natl Cancer Inst (2010) 1.09
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One (2012) 1.08
L2, the minor capsid protein of papillomavirus. Virology (2013) 1.07
The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA binding. J Virol (2004) 1.06
Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Res (2006) 1.06
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine (2008) 1.05
Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res (2011) 1.05
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine (2010) 1.05
Population genetics of Neisseria gonorrhoeae in a high-prevalence community using a hypervariable outer membrane porB and 13 slowly evolving housekeeping genes. Mol Biol Evol (2005) 1.05
Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women. Cytokine (2011) 1.04
Prediagnostic circulating antibodies to JC and BK human polyomaviruses and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev (2006) 1.03
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Papillomavirus prophylactic vaccines: established successes, new approaches. J Virol (2009) 1.00
Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol (2005) 1.00
Photonic approach to the selective inactivation of viruses with a near-infrared subpicosecond fiber laser. J Biomed Opt (2010) 0.99
p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol (2009) 0.99
No excess risk for colorectal cancer among subjects seropositive for the JC polyomavirus. Int J Cancer (2007) 0.99
Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev (2010) 0.98
Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol (2011) 0.97
Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility. Am J Pathol (2007) 0.96
Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clin Cancer Res (2013) 0.96
BK virus-specific antibodies and BKV DNA in renal transplant recipients with BKV nephritis. Am J Transplant (2005) 0.96
Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics. Proteomics (2011) 0.96
Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men. Cancer Epidemiol Biomarkers Prev (2012) 0.95
Optimization of multimeric human papillomavirus L2 vaccines. PLoS One (2013) 0.95
Development of a DNA vaccine targeting Merkel cell polyomavirus. Vaccine (2011) 0.95
Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma. Int J Cancer (2005) 0.93
Population dynamics of Neisseria gonorrhoeae in Shanghai, China: a comparative study. BMC Infect Dis (2010) 0.93
Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. Clin Vaccine Immunol (2006) 0.93
Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population. Clin Vaccine Immunol (2008) 0.92
Prospective study of JC virus seroreactivity and the development of colorectal cancers and adenomas. Cancer Epidemiol Biomarkers Prev (2009) 0.92
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92
Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am J Pathol (2008) 0.92
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol (2013) 0.92
Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol (2010) 0.92
Simian virus 40 (SV40) and human cancer: a review of the serological data. Rev Med Virol (2004) 0.91
Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines (2013) 0.90
Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients. J Med Virol (2009) 0.89
Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species. Virology (2012) 0.89
Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review. J Adolesc Health (2012) 0.89
Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients. PLoS Pathog (2012) 0.88
Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland. Clin Vaccine Immunol (2008) 0.87
Disease progression and evolution of the HIV-1 env gene in 24 infected infants. Infect Genet Evol (2007) 0.87
Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells. PLoS One (2011) 0.87
The future of vaccines for cervical cancer. Gynecol Oncol (2008) 0.87
Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen. Cell Biosci (2012) 0.86
Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms. Schizophr Bull (2009) 0.86